Breast Cancer

Research conducted at University of Kuopio has updated our knowledge about breast cancer

Published in Clinical Oncology Week, March 24th, 2008

"Mutations in the BRCA1/2 genes confer a high risk for breast and ovarian cancer, with usually adverse clinical characteristics. The clinical course and response to treatment in mutation carriers have been reported infrequently and are assumed to be worse than in sporadic breast cancer," scientists in Kuopio, Finland report.

"Eleven members of an Eastern Finnish family with multiple cases of breast and ovarian cancers were screened for BRCA1/2 mutations using protein truncation test (PTT), conformation-sensitive gel electrophoresis (CSGE) and sequencing. Five of the six BRCA2 4088insA mutation carriers were affected. Mutation-positive breast/ovarian cancer patients had...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Clinical Oncology Week

Source: Clinical Oncology Week (2008-03-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry